Navigation Links
Patient Survival Rises When Drugs Suppress Hepatitis C in Blood: Study
Date:12/25/2012

TUESDAY, Dec. 25 (HealthDay News) -- Patients with hepatitis C who have no detectable virus in their blood for six months after treatment are less likely to die than those who don't have this "sustained viral response" after treatment, a new study finds.

"Sustained viral response was associated with prolonged overall survival," wrote a Dutch team led by Dr. Adriaan van der Meer, of Erasmus MC University Medical Center, Rotterdam. "The risk of all-cause mortality was almost fourfold lower in [these] patients" compared to patients whose viral load was not suppressed for six months or more, they said.

In the article, published in the Dec. 26 issue of the Journal of the American Medical Association, the researchers noted that "chronic hepatitis C virus infection is a major cause of cirrhosis, hepatocellular carcinoma [liver cancer], and end-stage liver disease," and the incidence of these types of virus-linked illnesses "is expected to increase in upcoming years."

The researchers cited a prior study that estimated that about one-quarter of the 3.5 million Americans with chronic hepatitis C infection will develop cirrhosis, and that number could rise to 45 percent by 2030.

In the new study, van der Meer's team looked at 530 hepatitis C patients with advanced liver fibrosis, which is scarring that occurs in response to liver damage. The Canadian and European patients began interferon-based treatment between 1990 and 2003, and were followed for a median of more than eight years.

Among the patients, 192 (36 percent) achieved sustained viral response, according to a journal news release. However, only 13 of the patients with a sustained response died, compared to 100 of those patients who did not maintain viral suppression, the researchers found.

Of the deaths in the 100 patients without sustained viral response, the cause was liver-related in 70 patients, non-liver-related in 15 patients, and unknown in the other 15 patients.

Van der Meer's team determined that the 10-year, all-cause death rate was about 9 percent among patients with sustained viral response and 26 percent among those without this response -- a significant difference.

Further analysis showed that sustained viral response was associated with a reduced risk of all-cause death, liver-related death, and liver transplantation.

The 10-year rate of liver-related death or liver transplantation was about 2 percent in patients with a sustained viral response but more than 27 percent in those without it, the researchers reported. The 10-year rate of liver cancer was about 5 percent in patients with good responses and nearly 22 percent for those who did not respond to treatment as well.

Finally, the 10-year rate of liver failure was about 2 percent in patients with a sustained viral response and almost 30 percent in those without it, the investigators found.

More information

The U.S. National Institute of Allergy and Infectious Diseases has more about hepatitis C.

-- Robert Preidt

SOURCE: Journal of the American Medical Association, news release, Dec. 25, 2012


'/>"/>
Copyright©2012 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Higher-spending hospitals have fewer deaths for emergency patients
2. Researchers uncover a viable way for colorectal cancer patients to overcome drug resistance
3. Vaccine yielded encouraging long-term survival rates in certain patients with NSCLC
4. Study finds doctors have exaggerated fears when starting patients on insulin
5. Diagnostic Scans Tied to Radiation Risk for Gastro Patients
6. Predictors identified for rehospitalization among post-acute stroke patients
7. Pulse pressure elevation could presage cerebrovascular disease in Alzheimers patients
8. Breast cancer patients suffer treatment-related side effects long after completing care
9. Heart failure patients with diabetes may benefit from higher glucose levels
10. Gastro Woes Often Strike Rheumatoid Arthritis Patients
11. Short Walks May Ease Fatigue in Pancreatic Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Patient Survival Rises When Drugs Suppress Hepatitis C in Blood: Study
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... ... today announced the release of two biometric time and attendance tracking products: the ... 4.0 software. NCheck Cloud Bio Attendance uses biometric face recognition to enable ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... The Executives, ... to raise money to for the Toys for Tots Literacy Campaign at their Semi-Annual ... in excess of $70 billion, the U.S. ranks at number 14 internationally in literacy. ...
(Date:3/28/2017)... ... March 28, 2017 , ... Prominant bariatric surgeon ... is thrilled to offer the recently FDA-approved Obalon Balloon System to his patients. ... SkyLex Advanced Surgical’s already comprehensive list of weight-loss services. Dr. Liu is ...
(Date:3/28/2017)... Francisco, CA (PRWEB) , ... March 28, 2017 , ... ... treatment, is proud to announce a new blog post about women’s hair loss. Although ... suffer from hair loss as they age. Menopause or genetics can be two reasons ...
(Date:3/28/2017)... ... , ... “A Prophets Bones”: a thrilling adventure that reveals the mystery of Kevin’s purpose. “A ... his parents and teachers had asked of him that he had neglected to do, but ... the Almighty Creator. There were some who would have felt themselves to be special and ...
Breaking Medicine News(10 mins):
(Date:3/28/2017)... , March 28, 2017  Medeon Biodesign, ... device company, is pleased to announce that the ... investment of Panther Orthopedics, Inc., a ... dynamic fixation solutions for orthopedic extremity applications.  ... to expand rapidly, primarily due to procedure volume ...
(Date:3/27/2017)... , March 27, 2017 ... clinical-stage pharmaceutical company specializing in the development of cannabinoid-based ... offering in the United States ... ADS representing 40 ordinary shares of the Company, ... addition, Therapix has granted the underwriters a 45-day ...
(Date:3/27/2017)... Medtec Europe will once ... 600 exhibitors from 70 countries the opportunity to ... will advance the medical technology industry. Taking place ... Stuttgart, Stuttgart, Germany , Medtec ... the key trends and insights across the entire ...
Breaking Medicine Technology: